Clonal Evolution of Glioblastoma under Therapy

By Jiguang Wang, Emanuela Cazzato, Erik Ladewig, V. Frattini, Daniel I. S. Rosenbloom, Sakellarios Zairis, F. Abate, Zhaoqi Liu, Oliver Elliott, Y. Shin and 10 more. Nature Genetics, 2016

667 citations recorded by the source corpus.

Glioblastoma (GBM) is the most common and aggressive primary brain tumor. To better understand how GBM evolves, we analyzed longitudinal genomic and transcriptomic data from 114 patients. The analysis shows a highly branched evolutionary pattern in which 63% of patients experience expression-based subtype changes. The branching pattern, together with estimates of evolutionary rate, suggests that relapse-associated clones typically existed years before diagnosis. Fifteen percent of tumors present hypermutation at relapse in highly expressed genes, with a clear mutational signature. We find that 11% of recurrence tumors harbor mutations in LTBP4, which encodes a protein binding to TGF-β. Silencing LTBP4 in GBM cells leads to suppression of TGF-β activity and decreased cell proliferation. In recurrent GBM with wild-type IDH1, high LTBP4 expression is associated with worse prognosis, highlighting the TGF-β pathway as a potential therapeutic target in GBM.

Subfields: Cancer Research, Cell Biology, Genetics

View Paper: https://www.semanticscholar.org/paper/1bb25ec98e1a3bbfd101a2a09f1d7470563da2c7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

  1. Timothy A. Chan
  2. J. Havel
  3. N. Riaz
  4. A. Desrichard
  5. V. Makarov
  6. Matthew Smith-Cohn
  7. H. Colman
  8. A. Cohen

Citations in the corpus